Clearside Biomedical Inc expected to post a loss of 14 cents a share - Earnings Preview

Clearside Biomedical,

12/08/2023 03:04

* Clearside Biomedical Inc  CLSD.OQ   CLSD.O  is expected
to show
a fall in quarterly revenue when it reports  results on August
14. 
    * The Alpharetta Georgia-based  company is expected to
report  a
67.7% decrease in revenue to $124.2 thousand from $384 thousand
a year ago, according to the mean estimate from 5 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Clearside
Biomedical Inc
is for a loss of 14 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Clearside
Biomedical Inc is $5.5​, above​ its last closing price of $1.05.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.14       -0.14      -0.15     Missed  -7.1
 Dec. 31 2023  -0.13       -0.13      -0.16     Missed  -27
 Sep. 30 2022  -0.05       -0.03      -0.13     Missed  -282.4
                                                        ​
 Jun. 30 2022  -0.13       -0.13      -0.13     Met     1.5
 ​​Mar.        -0.08       -0.08      -0.13     Missed  -58.5
 31 2022                                                
 Dec. 31 2021  0.12        0.16       0.31      Beat    95.8​
 Sep. 30 2021  -0.10       -0.08      -0.08     Met     5.9
 Jun. 30 2021  -0.13       -0.13      -0.11     Beat    14.3
 This summary was machine generated August 12 at 02:03 GMT.  All
figures in US dollars  unless otherwise stated